Recurrent thrombosis followed by Lazarus response in ROS1 rearranged NSCLC treated with crizotinib: a case report.

CONCLUSIONS: Cancer diagnosis should always be considered in patients with unprovoked thrombosis and, if NSCLC is diagnosed, genetic alterations should be always sought after. A possible relation between venous thromboembolism and oncogenic drivers, particularly for ALK translocations, has been hypothesized. Similarly to ALK-positive NSCLC, ROS1 rearranged disease has been associated with an increased thromboembolic risk. Further studies are needed to better evaluate this relation and to evaluate the potential benefit of a prophylactic anticoagulating treatment in this subset of patients. PMID: 32066344 [PubMed - as supplied by publisher]
Source: Tumori - Category: Cancer & Oncology Tags: Tumori Source Type: research

Related Links:

Publication date: Available online 4 April 2020Source: Radiation Physics and ChemistryAuthor(s): B. Juste, R. Miró, S. Morató, G. Verdú, S. Peris
Source: Radiation Physics and Chemistry - Category: Physics Source Type: research
Publication date: Available online 5 April 2020Source: Journal of Molecular StructureAuthor(s): T. Valarmathi, R. Premkumar, A. Milton Franklin Benial
Source: Journal of Molecular Structure - Category: Molecular Biology Source Type: research
Publication date: Available online 4 April 2020Source: Redox BiologyAuthor(s): Raúl González, María A. Rodríguez-Hernández, María Negrete, Kalina Ranguelova, Aurelie Rossin, Carmen Choya-Foces, Patricia de la Cruz-Ojeda, Antonio Miranda-Vizuete, Antonio Martínez-Ruiz, Sergio Rius-Pérez, Juan Sastre, José A. Bárcena, Anne-Odile Hueber, C. Alicia Padilla, Jordi Muntané
Source: Redox Biology - Category: Biology Source Type: research
CONCLUSIONS: This study suggests that MTC is a more immunologically active tumor that has been previously reported. Patients with advanced MTC should be screened for targetable antigens and immune checkpoints to determine their eligibility for current clinical trials. Additional studies are necessary to fully characterize the antigenic potential of MTC and may encourage the development of adoptive T cells therapies for this rare tumor. PMID: 32242507 [PubMed - as supplied by publisher]
Source: Thyroid : official journal of the American Thyroid Association - Category: Endocrinology Tags: Thyroid Source Type: research
Publication date: Available online 4 April 2020Source: Journal of Environmental PsychologyAuthor(s): Kati Peditto, Mardelle Shepley, Naomi Sachs, Jane Mendle, Anthony Burrow
Source: Journal of Environmental Psychology - Category: Psychiatry & Psychology Source Type: research
Dr. Matija Snuderl, neuropathologist and molecular pathologist at  New York University Langone Health, was featured ina recent article appearing inNature (March 26, 2020, Vol 579, p S14-S16). The article, which addresses the use of artificial intelligence (AI) in cancer diagnostics, opens with Dr. Snuderl experiencing a moment that many of us neuropathologists have had wherein we hesitate before signing out a case because of a feeling that something might be just a bit different about a particular specimen. That feeling prompts us to do something else (run more ancillary testing, get a consult, sleep on it and ta...
Source: neuropathology blog - Category: Radiology Tags: neuropathologists Source Type: blogs
This study delves into the mechanisms by which a short period of fasting can accelerate wound healing. Fasting triggers many of the same cellular stress responses, such as upregulated autophagy, as occur during the practice of calorie restriction. It isn't exactly the same, however, so it is always worth asking whether any specific biochemistry observed in either case does in fact occur in both situations. In particular, the period of refeeding following fasting appears to have beneficial effects that are distinct from those that occur while food is restricted. Multiple forms of therapeutic fasting have been repor...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Authors: Gachabayov M, Dong XD, Latifi R, Bergamaschi R PMID: 32244258 [PubMed - as supplied by publisher]
Source: Surgical Technology International - Category: Surgery Tags: Surg Technol Int Source Type: research
Authors: Li T, Yuan D, Yuan J Abstract Thrombosis, the localized clotting of blood that affects arterial or venous circulation, is one of the leading causes of death worldwide. Arterial thrombosis is commonly initiated by vascular endothelial injury, while venous thrombosis mainly stems from blood stasis. Despite these differences, platelet adhesion, activation and aggregation, and fibrin formation as a result of coagulation constitute the fundamental processes of thrombus formation. Antithrombotic drugs permitted on the clinical currently can dramatically reduce major adverse cardiovascular events; however, they c...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
Authors: Yamaguchi T, Gotoh Y, Hattori H, Katsuno H, Imaizumi K Abstract A previous randomized phase II study in patients with non-small cell lung cancer (NSCLC) identified that combination treatment with erlotinib plus bevacizumab prolonged progression-free survival compared with erlotinib alone. However, combination bevacizumab and erlotinib treatment generally increased the risk of severe adverse events, including hemorrhage, thrombosis, fistula formation and gastrointestinal perforation. The present report describes two patients with NSCLC harboring epidermal growth factor receptor (EGFR) mutations, who experie...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Cardiology | Genetics | Heart | Lung Cancer | Non-Small Cell Lung Cancer | Pulmonary Thromboembolism | Respiratory Medicine | Study | Thrombosis